NASDAQ: RENB - Renovaro Biosciences Inc.

Lønnsomhet i seks måneder: -40.83%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Renovaro Biosciences Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Renovaro Biosciences Inc.

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

flere detaljer
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2015-02-02
ISIN US29350E1047
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.renovarobio.com
Цена ао 2.92
Prisendring per dag: +1.17% (0.9065)
Prisendring per uke: -44.08% (1.64)
Prisendring per måned: +50.27% (0.6103)
Prisendring over 3 måneder: +86.02% (0.493)
Prisendring over seks måneder: -40.83% (1.55)
Prisendring per år: -71.07% (3.17)
Prisendring over 3 år: -91.04% (10.23)
Prisendring over 5 år: -84.69% (5.99)
Prisendring over 10 år: 0% (0.9171)
Prisendring siden begynnelsen av året: +76.71% (0.519)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 1.17 9
P/E 0 0
EV/EBITDA -1.99 0
Total: 3.13

Effektivitet

Navn Betydning Karakter
ROA, % -72.84 0
ROE, % -90.37 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0476 10
Total: 9

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 42.56 6
Lønnsomhet Ebitda, % 609.97 10
Lønnsomhet EPS, % 241.32 10
Total: 7.4
Flere detaljer

Institusjoner Volum Dele, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.00641 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00112 38.04 0.6026
ProShares UltraPro Russell2000 0.00055 89.82 1.47873
ProShares Hedge Replication ETF 0.00016 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



Veileder Stillingstittel Betaling Fødselsår
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (61 år)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (62 år)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (64 år)

Adresse: United States, Los Angeles. CA, 2080 Century Park East - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.renovarobio.com